Antibodies
19 October 2023
Sutro Demonstrates Meaningful ADC Innovation with Five Presentations and One Poster at the 14th Annual World ADC Conference19 October 2023
Bolt Biotherapeutics Announces First Patient Dosed in Phase 1/2 Study of BDC-3042 in Patients with Advanced Cancers19 October 2023
Y-mAbs Therapeutics Announces U.S. FDA Clearance of Investigational New Drug Application for CD38-SADA19 October 2023
CytomX Therapeutics Presents Preclinical Profile of EpCAM-directed Antibody Drug Conjugate CX-2051 at 2023 World ADC Conference18 October 2023
BIMZELX® Approved by the U.S. FDA for the Treatment of Adults with Moderate to Severe Plaque Psoriasis16 October 2023
Samsung Bioepis Presents Phase 1 and 3 Clinical Results for SB16, a Proposed Biosimilar to Proliaⁱ (denosumab), at ASBMR 202316 October 2023
LegoChem Biosciences Enters Worldwide Licensing Agreement with Glycotope for Antibody Drug Conjugate Development16 October 2023
OSE Immunotherapeutics Presents First Positive Clinical Results With its anti-PD1 OSE-279 in Advanced Solid Tumors16 October 2023
SOTIO Further Expands Next-Generation ADC Platform with License to Synaffix’s ADC Technology15 October 2023
Late-breaking amlitelimab Phase 2b data presented at EADV show potential best-in-class profile in atopic dermatitis11 October 2023
Temtokibart achieves First Subject First Treatment (FSFT) milestone in Phase 2b trial10 October 2023
RAD receives approval for Phase 1 therapeutic study of PDL1-nanobody in Non-Small Cell Lung CancerNews Channels
Newsletter
La Merie Biologics
La Merie Publishing releases a weekly newsletter with a focus on biopharmaceutical research and development.
Subscribe
Newsletter
New Product Alert
La Merie Publishing offers an e-mail notification service about the release of new products of La Merie Publishing. This New Product Release Alert also informs about the release of FREE reports produced by La Merie Publishing.
Subscribe
Featured reports